Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Pawlyn

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Physiotherapy|May 1, 1978
Grading criteriaC Pawlyn, R West
Expert Opinion on Drug Safety|February 26, 2016
The safety of pomalidomide for the treatment of multiple myelomaJ R Jones, C Pawlyn, F E Davies, et al.
Leukemia|December 10, 2015
Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma?C Pawlyn, L Fowkes, S Otero, et al.
Blood Cancer Journal|March 19, 2024
Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometryH V Giles, M T Drayson, B Kishore, et al.
Leukemia|August 10, 2021
Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugsJ R Jones, A Barber, Y-V Le Bihan, et al.
Blood Cancer Journal|April 1, 2017
Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle controlC Pawlyn, M D Bright, A F Buros, et al.
Blood Cancer Journal|December 10, 2016
Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trialJ R Jones, D A Cairns, W M Gregory, et al.
Leukemia|June 7, 2017
Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patientsV Shah, A L Sherborne, B A Walker, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Physiotherapy|May 1, 1978
Grading criteriaC Pawlyn, R West
Expert Opinion on Drug Safety|February 26, 2016
The safety of pomalidomide for the treatment of multiple myelomaJ R Jones, C Pawlyn, F E Davies, et al.
Leukemia|December 10, 2015
Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma?C Pawlyn, L Fowkes, S Otero, et al.
Blood Cancer Journal|March 19, 2024
Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometryH V Giles, M T Drayson, B Kishore, et al.
Leukemia|August 10, 2021
Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugsJ R Jones, A Barber, Y-V Le Bihan, et al.
Blood Cancer Journal|April 1, 2017
Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle controlC Pawlyn, M D Bright, A F Buros, et al.
Blood Cancer Journal|December 10, 2016
Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trialJ R Jones, D A Cairns, W M Gregory, et al.
Leukemia|June 7, 2017
Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patientsV Shah, A L Sherborne, B A Walker, et al.
Pageof 1